JUNO PHARMACEUTICALS INC. & DESIGN — 1657196
Numéro de demande
1657196
Numéro d'enregistrement
TMA1015650
Type(s)
Dessin
Catégorie
Marque de commerce
Statut de l'OPIC
CANCELLED BY OWNER
Statut de TM5
INACTIF/ENREGISTREMENT/A
fait l’objet d’une renonciation
La marque demandée a été enregistrée mais a été ultérieurement, sur une base volontaire, supprimée du registre par le titulaire.
Produite
2013-12-19
Inactive
2024-03-21
Propriétaire inscrit
Juno Pharmaceuticals Inc.
65B West Beaver Creek
Richmond Hill
ONTARIO L4B1K4
Agent
KENNETH R. CLARK
(AIRD & BERLIS LLP)
BROOKFIELD PLACE, SUITE 1800
181 BAY STREET
TORONTO
ONTARIO M5J2T9
Documents
Rubriques d'index
- J JUNO PHARMACEUTICALS INC.
Information sur les codes de Viennes (Code & Description)
- 26.1.1
- Cercles
- A 26.1.3
- Un cercle ou une ellipse
- A 26.1.18
- Cercles ou ellipses contenant une ou plusieurs lettres
- 29.1.4
- Bleu
- 29.1.6
- Blanc, gris, argent
Revendication de couleur
Colour is claimed as a feature of the trade-mark. The colours blue, navy blue and grey are claimed as a feature of the mark. The word "juno" is in grey as described in the cyan magenta yellow key (black) system (cmyk system) as c=63, m=55, y=55, k=30 and the dot above the "j" in the word "juno" is described in the cyan magenta yellow key (black) system (cmyk system) as c=55, m=3, y=0, k=0. The words "pharmaceuticals inc." is in grey described in the cyan magenta yellow key (black) system (cmyk system) as c=63, m=55, y=55, k=30. The circle portion of the mark is a blue colour with C:55, M:3, Y:0 and K:0. The left side of the inside circle component is described as C:20, M:0, Y:3, K:0. The middle of the inside circle component is described as C:85, M:50, Y:8, K: 0. The right side of the insider cicle component is described as C:76, M:31, Y:20, K:1
Produits (Classe de Nice & Énoncé(s))
- (1) Pharmaceutical preparations, namely, preparations for the prevention and treatment of cancers; pharmaceutical preparations, namely, platelet stimulating factors; pharmaceutical cardiovascular preparations.
- (2) Pharmaceutical preparations for the treatment of cardiovascular disease, urological disorders, gastrointestinal disorders, allergies, diabetes, hypertension, erectile dysfunction, sexual dysfunction, stroke, cancer, migraines, obesity and respiratory diseases, fungal disorders; pharmaceutical preparations, namely anti-inflammatory analgesics; pharmaceutical preparations, namely, cholesterol preparations, smoking cessation preparations, skin repair preparations.
- (3) Pharmaceutical preparations for the treatment of diabetes, cancer; pharmaceutical preparations consisting of protein kinase or phosphatase; diagnostic reagents for scientific or medical research use; scientific and medical compounds, namely, protein kinases and phosphatases.
- (4) Pharmaceutical preparations for the prevention and/or treatment of cancer, carcinomas and sarcomas; pharmaceutical preparations for the prevention and/or treatment of cancerous tumours.
- (5) Pharmaceutical preparations for the treatment of pains, fever, angina, otorhinolaryngology, gastric and liver illnesses, heart illnesses, arterial and venous illnesses, rheumatic illnesses, namely osteoarthritis, rheumatoid arthritis, lupus, ankylosing spondylitis, Sjogren's syndrome, gout, fibromyalgia, and polymyalgia rheumatica; anaesthetics, analgesics, frostbite salve for pharmaceutical purposes, haemorrhoid preparations, pharmaceutical preparations for the treatment of headaches, salts for medicated baths, mouthwashes for medical purposes, tranquillizers, sedatives, tobacco free cigarettes for smoking cessation treatments, medicines for alleviating constipation, contraceptives chemicals, radiological contrast substances for medical purposes, diagnostic preparations for medical purposes, namely lubricants and gels for ultrasound and gynecological diagnostic procedures; drugs for the treatment of pain, fever, angina otorhinolaryngology, gastric and liver' illnesses, heart illnesses, arterial and venous illnesses, and rheumatic illnesses, namely osteoarthritis, rheumatoid arthritis, lupus, ankylosing spondylitis, Sjogren's syndrome, gout, fibromyalgia, and polymyalgia rheumatica; mineral water.
- (6) Pharmaceutical preparations for the treatment of smooth muscle disorders, namely stroke, Parkinson's disease, multiple sclerosis, Huntington's disease, Creutzfeldt-Jakob disease, Amyotrophic lateral sclerosis, muscular dystrophy, inflammatory myopathies, and dystonias, headacties, wrinkles, hyperhydrosis, sports injuries, namely, injured or torn skin, muscle, ligaments or bone, tremors, namely, spasmodic smooth, striated or cardiac muscles; and pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labour pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, /cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain/ spasmodic cardiac muscles; pharmaceutical preparations for the treatment of cerebral palsy.
- (7) Pharmaceutical preparations and substances, namely anti-infectives, anti-bacterials, antibiotics, antivirals, antidiabetic preparations, cardiovascular preparations, hemostatic agents, pharmaceutical preparations and substances for the treatment of cancer, HIV, obesity, and respiratory and urologic disorders and diseases; pharmaceutical preparations and substances for the treatment of acute ischemic stroke and traumatic brain injury (TBI), cerebral vasodilators.
- (8) Prescription pharmaceutical preparations and substances for the prevention and treatment of diseases and disorders of the respiratory system, peripheral nervous system, namely diabetic nerve problems, Guillaume-Barr syndrome, carpal tunnel syndrome, thoracic outlet syndrome, complex regional pain and brachial plexus injuries, cardiovascular system, gastro-intestinal system; prescription pharmaceutical preparations and substances for use in pain control, anaesthesia, oncology; prescription pharmaceutical preparations and substances for the treatment and prevention of diabetes.
- (9) Pharmaceutical preparation and substances, namely hematinics which increase the hemoglobin content of the blood.
Services (Classe de Nice & Énoncé(s))
(1) Consulting and operations services namely the obtaining of pharmaceutical regulatory licences and intellectual property licences for others.
Information relative de classification
Mise en garde
Les données relatives à la classification sont fournies à des fins d’information et de recherche seulement. L’OPIC ne garantit pas l’exactitude des classes attribuées à la marque de commerce. Ces données n’ont aucune valeur juridique.
- 1 - Chimiques et adhésifs
- 5 - Pharmaceutiques et herbicides
- 45 - Personnels et juridiques
Revendication(s)
- Declaration of Use filed February 01, 2019
Historique des actions
| Action | Date de l'action | Date d'échéance | Commentaires |
|---|---|---|---|
| Produite | 2013-12-19 | ||
| Créé | 2013-12-20 | ||
| Formalisée | 2014-01-03 | ||
| Recherche enregistrée | 2014-08-28 | ||
| Premier rapport de l'examinateur | 2014-08-28 | 2015-02-28 | |
| Correspondance créée | 2015-03-18 | 2015-09-18 | |
| Avis de défaut envoyé | 2015-10-06 | 2015-12-06 | |
| Avis d'approbation envoyé | 2015-10-20 | 2015-11-17 | |
| Défaut enlevé | 2015-10-20 | ||
| Approuvée | 2015-12-10 | APPROVED BY PROGRAM EX200M1 | |
| Publiée | 2015-12-30 | Vol.62 Issue 3192 | |
| Opposition projetée | 2016-02-12 | Proposed Opposition Filed by receiving mail. | |
| Opposée | 2016-11-29 | Opposition Filed. | |
| Opposition enlevée | 2019-01-14 | Case Closed - Opponent Withdraws 91 | |
| Admise | 2019-01-18 | ||
| Avis d'admission envoyé | 2019-01-18 | 2019-07-18 | |
| Enregistrée | 2019-02-21 | 2034-02-21 | |
| Annulée par le propriétaire | 2024-03-21 | Cancelled under section 41(1)(b) as of 2024-Mar-21 |
Historique d'opposition
CAS # 1 : JUNO THERAPEUTICS, INC. - Closed
| Action | Date de l'action | Date d'échéance |
|---|---|---|
| Cause fermée - Retrait de l'opposant | 2019-01-14 |
Déclaration d'opposition
| Action | Date de l'action | Date d'échéance |
|---|---|---|
| Prolongation de délai accordée à l'opposant | 2016-02-12 | |
| Prolongation de délai accordée à l'opposant - Conciliation | 2016-06-08 | |
| Prolongation de délai accordée à l'opposant | 2016-09-13 | |
| Droits relatifs à la déclaration d'opposition reçus | 2016-11-29 | |
| Déclaration d'opposition déposée | 2016-11-29 | |
| Déclaration d'opposition transmise à des fins d'examen | 2016-12-01 | |
| Déclaration d'opposition envoyée au requérant | 2016-12-06 | 2017-02-06 |
Contre-déclaration
| Action | Date de l'action | Date d'échéance |
|---|---|---|
| Contre-déclaration déposée par le requérant | 2016-12-21 | |
| Contre-déclaration signifiée à l'opposant | 2016-12-21 | 2017-04-21 |
Preuve - Opposant
| Action | Date de l'action | Date d'échéance |
|---|---|---|
| Preuve déposée par l'opposant | 2017-04-21 | |
| Preuve signifiée au requérant | 2017-04-21 | 2017-12-31 |
Preuve - Requérant
| Action | Date de l'action | Date d'échéance |
|---|---|---|
| Prolongation de délai accordée au requérant | 2017-09-11 | |
| Preuve déposée par le requérant | 2017-12-29 | |
| Preuve signifiée à l'opposant | 2017-12-29 | 2018-01-29 |
Contre-preuve
| Action | Date de l'action | Date d'échéance |
|---|---|---|
| Aucune preuve en réplique par l'opposant | 2018-01-29 | 2018-03-29 |
Plaidoyers écrits
| Action | Date de l'action | Date d'échéance |
|---|---|---|
| Plaidoyers écrits demandés - Opposant | 2018-05-08 | 2018-06-08 |
| Plaidoyers écrits demandés - Requérant | 2018-05-08 | 2018-06-08 |
| Déclaration - Aucun plaidoyer écrit du requérant | 2018-05-29 | |
| Déclaration - Aucun plaidoyer écrit de l'opposant | 2018-06-08 | |
| Correspondance produite | 2018-06-14 | |
| Plaidoyers écrits échangés | 2018-06-14 | 2018-07-14 |
Audience
| Action | Date de l'action | Date d'échéance |
|---|---|---|
| Demande d'audience par le requérant | 2018-07-03 | |
| Cause transmise pour audience | 2018-07-10 | |
| Demande d'audience par l'opposant | 2018-07-18 |
Contre-interrogatoire par le requérant
| Action | Date de l'action | Date d'échéance |
|---|---|---|
| Contre-interrogatoire de l'opposant demandé | 2017-04-26 | |
| Contre-interrogatoire ordonné de l'opposant | 2017-05-11 | 2017-09-11 |
| Correspondance produite | 2017-05-11 | |
| Avis de contre-interrogatoire envoyé à l'opposant - 4 + 4 mois | 2017-05-11 | |
| Transcription du contre-interrogatoire deposée par le requérant | 2017-08-31 |